1. Home
  2. NUVB vs HELE Comparison

NUVB vs HELE Comparison

Compare NUVB & HELE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • HELE
  • Stock Information
  • Founded
  • NUVB 2018
  • HELE 1968
  • Country
  • NUVB United States
  • HELE United States
  • Employees
  • NUVB N/A
  • HELE N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • HELE Home Furnishings
  • Sector
  • NUVB Health Care
  • HELE Consumer Discretionary
  • Exchange
  • NUVB Nasdaq
  • HELE Nasdaq
  • Market Cap
  • NUVB 679.9M
  • HELE 642.2M
  • IPO Year
  • NUVB N/A
  • HELE N/A
  • Fundamental
  • Price
  • NUVB $1.95
  • HELE $26.73
  • Analyst Decision
  • NUVB Strong Buy
  • HELE Buy
  • Analyst Count
  • NUVB 6
  • HELE 3
  • Target Price
  • NUVB $7.83
  • HELE $56.33
  • AVG Volume (30 Days)
  • NUVB 7.8M
  • HELE 603.9K
  • Earning Date
  • NUVB 08-04-2025
  • HELE 07-08-2025
  • Dividend Yield
  • NUVB N/A
  • HELE N/A
  • EPS Growth
  • NUVB N/A
  • HELE N/A
  • EPS
  • NUVB N/A
  • HELE 5.37
  • Revenue
  • NUVB $10,957,000.00
  • HELE $1,907,665,000.00
  • Revenue This Year
  • NUVB $106.80
  • HELE $0.44
  • Revenue Next Year
  • NUVB $320.63
  • HELE $0.99
  • P/E Ratio
  • NUVB N/A
  • HELE $4.98
  • Revenue Growth
  • NUVB N/A
  • HELE N/A
  • 52 Week Low
  • NUVB $1.54
  • HELE $24.15
  • 52 Week High
  • NUVB $3.97
  • HELE $100.65
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 44.43
  • HELE 43.16
  • Support Level
  • NUVB $1.58
  • HELE $25.93
  • Resistance Level
  • NUVB $1.89
  • HELE $28.18
  • Average True Range (ATR)
  • NUVB 0.23
  • HELE 1.24
  • MACD
  • NUVB -0.06
  • HELE 0.11
  • Stochastic Oscillator
  • NUVB 33.04
  • HELE 27.25

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

About HELE Helen of Troy Limited

Helen Of Troy Ltd is a consumer products company offering creative products and solutions for its customers through a diversified portfolio of brands. It has two operating segments: Home and Outdoor segment provides a broad range of consumer products for home activities such as food preparation, cooking, cleaning, and organization; as well as products for outdoor and on-the-go activities such as hydration, food storage, backpacks, and travel gear, and The Beauty and Wellness segment provides beauty and wellness products including mass and prestige market beauty appliances, prestige market liquid-based hair and personal care products, and wellness devices including thermometers, water and air filtration systems, humidifiers, and fans.

Share on Social Networks: